scispace - formally typeset
Open AccessJournal ArticleDOI

Yttrium-90 radioembolization of liver tumors: what do the images tell us?

Pavel Singh, +1 more
- 01 Jan 2013 - 
- Vol. 13, Iss: 4, pp 645-657
Reads0
Chats0
TLDR
This review provides a comprehensive description of the different findings seen in post-treatment scans, with the aim of facilitating appropriate radiological interpretation of post-TARE pathologic changes, notwithstanding their existing limitations.
Abstract
Transarterial radioembolization (TARE) with yttrium 90 microspheres is an increasingly popular therapy for both primary and secondary liver malignancies. TARE entails delivery of β-particle brachytherapy and embolization of the tumor vasculature. The consequent biological sequelae are distinct from those of other transarterial therapies for liver tumors, as reflected in the often baffling post-treatment imaging features. As the clinical use of TARE is increasing, more diverse post-treatment radiological findings are encountered with variable overlap among treatment response, residual disease, reactionary changes and complications. Thus, post-TARE image interpretation is challenging. This review provides a comprehensive description of the different findings seen in post-treatment scans, with the aim of facilitating appropriate radiological interpretation of post-TARE pathologic changes, notwithstanding their existing limitations.

read more

Citations
More filters
Journal ArticleDOI

Radioembolization of Colorectal Liver Metastases: Indications, Technique, and Outcomes.

TL;DR: Indications, contraindications, preprocedure evaluation, activity prescription, follow-up, outcomes, and complications of radioembolization of colorectal liver metastases are discussed.
Journal ArticleDOI

Expected and Unexpected Imaging Findings after 90Y Transarterial Radioembolization for Liver Tumors.

TL;DR: Correct treatment planning is essential to obtaining good results with TARE, as this treatment invariably results in some degree of irradiation of normal liver parenchyma, inducing different radiologic findings that may affect follow-up image interpretation and response evaluation.
Journal ArticleDOI

Imaging Evaluation Following 90Y Radioembolization of Liver Tumors: What Radiologists Should Know

TL;DR: The current concepts for assessing tumor response, common post-treatment imaging features, and associated complications following radioembolization are discussed.
Journal ArticleDOI

Evaluation of liver tumour response by imaging.

TL;DR: This clinical review focuses on the progress made in the evaluation of liver tumours on imaging, discussing the rationale for this approach, addressing challenges and controversies in the field, and suggesting possible future developments.
References
More filters
Journal ArticleDOI

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

TL;DR: A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines.
Journal ArticleDOI

EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma

TL;DR: The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
Journal ArticleDOI

Reporting results of cancer treatment.

TL;DR: Recommendations have been developed for standardized approaches to the recording of baseline data relating to the patient, the tumor, laboratory and radiologic data, the reporting of treatment, grading of acute and subacute toxicity, reporting of response, recurrence and disease‐free interval, and reporting results of therapy.
Journal ArticleDOI

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

TL;DR: A group of experts developed a set of guidelines aimed at providing a common framework for the design of clinical trials in HCC and adapted the concept of viable tumor-tumoral tissue showing uptake in arterial phase of contrast-enhanced radiologic imaging techniques-to formally amend RECIST, referred to herein as the modified RECIST assessment (mRECIST).
Related Papers (5)